News

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease
The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25 ...
PipelineReview.com30m
Lilly’s Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer’s disease
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having ...
AZoSensors on MSN1d
Fish Freshness: How AI and Biosensors Could Make a Difference
Combining AI with paper-based sensors, this research offers a new approach to seafood freshness assessment, ensuring quality ...
Novo Nordisk drops as GLP-1 headwinds prompt guidance cut; names new CEO
Novo Nordisk (NVO) stock falls as the company names a new CEO and cuts outlook citing pressure on obesity drug sales. Eli ...